Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Yeshiva University

Latest From Ono Pharmaceutical Co. Ltd.

Immuno-Oncology Outlook: Looking For Brain Cancer Options

Scrip analyses the potential of "hot" immunotherapy mechanisms, such as PD-1 inhibitors and CAR-T therapies, in various stages of clinical development for glioblastoma.

ImmunoOncology Research and Development Strategies

Open Innovation: The Fast-Track To Global Pharma Power For Korea?

Although South Korea has a good clinical trial infrastructure, workforce, and novel drug development technology, it still lacks the power to lead the development of new drugs across the finish line. The country needs to create an environment that can attract multinationals to co-research and co-develop drugs with domestic pharma firms under open innovation programs if Korea-originated blockbusters are ever to emerge, experts told a recent forum in Seoul.

South Korea Policy & Regulation

Deals Shaping The Medical Industry, June 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.

Deals BioPharmaceutical

Deal Watch: Array Partners With Ono On Cancer Drugs In Japan, South Korea

French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.

Deals Business Strategies
See All